论文部分内容阅读
在美国,一种三价皮内注射裂解流感病毒疫苗(IIV3-ID)(Fluzone~皮内,赛诺菲巴斯德,斯威夫特卫特,宾夕法尼亚州)自2011—2012年流感流行季一直被用于18~64岁成人。该研究旨在检测添加第2种B系毒株是否影响其免疫原性及安全性。这项随机、双盲、多中心试验评估了美国2012—2013年流感流行季18~64岁成人皮内注射四价裂解流感病毒疫苗(IIV4-ID)的免疫原性和安全性。参与者随机以2∶1∶1比例接受IIV4-ID、已注册的IIV3-
In the United States, a trivalent intradermic injection of a split influenza virus vaccine (IIV3-ID) (Fluzone®, Epilepsy, Sanofi Pasteur, Swiftville, Pa.) Since the 2011-2012 influenza season Has been used for adults 18 to 64 years old. The aim of this study was to determine whether the addition of a second B strain affects its immunogenicity and safety. This randomized, double-blind, multicentre trial evaluated the immunogenicity and safety of the U.S. intranasal IV tetravalent split influenza virus vaccine (IIV4-ID) between 18 and 64 years of age in the US for the period 2012-2013. Participants randomly received IIV4-ID in a 2: 1: 1 ratio, registered IIV3-